We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Agua de Madre is craft-brewed water kefir aimed at the evergrowing no- and low- alcohol UK market. It aims to be an ethical brand that makes a delicious drink with live bacteria up to 250 billion live cultures per 100ml. The naturally low-alcohol fizzy water kefir is sold in deli's, restaurants, bars, and other food stores in London. Agua de Madre has also attracted media interest from major publications including Metro, Vogue, and Wallpaper. Furthermore, the company is planning to maximise its production potential, hire a specialist sales agency Windfall, expand to sell further in southwest London, and ramp up marketing with its PR Agency, Visible.

Pitch Rated

50%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £250,990
A well-established money transfer service with more than 10,000 account holders, aiming to bridge the gap between unbanked businesses, merchants and individuals, no matter their locations in the world. Omanye is seeking investment to expand their current sites in Asia and Africa.
days to go: Expired investment: £129,090
TOTM makes organic, eco-friendly & reusable period care products. The company is planning to shake up the £29 billion Femcare industry, with 30k+ online and subscription customers, and listings in Tesco, Superdrug and Urban Outfitters and global B2B clients. Having supplied to large corporates including several global institutions, TOTM is ready for global disruption. To this end, the company is raising funds to accelerate global growth across all channels. The proceeds will also be used to expand its product range, grow awareness, secure more distribution and also invest in tech. 

Pitch Rated

77%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £811,400
Cranes Drinks is the fastest growing cider company in the UK, producing a range of innovative fruit ciders. By utilising the fruit’s natural sweetness, its drinks contain 30% fewer calories compared to that of brand leaders. Cranes ciders come in 3 flavours: blueberry & apple, cranberry & lime, and raspberry & pomegranate. As per Cranes, 34% of cider drinkers haven't consumed cider drinks much because it’s too sweet or has too much sugar. This makes Cranes a top contender in a growing fruit cider market worth £1.3 billion. The company's entire range is available on Ocado, and it has received 3 national listings in prominent retail chains like Sainsbury’s, Asda, and Morrisons. The brand has won 3 awards for its spirit range including a Gold Award in the Liqueur Masters organised by The Spirits Business and two awards from the International Wine & Spirits Competition. It has also received substantial media coverage in publications like Made In Chelsea, Dragons Dens, The Daily Telegraph, The Evening Standard, Vogue, Cosmopolitan, and Bella amongst others. With the investment, the company aims to use 25% of it as working capital, 60% in marketing, and 15% in managing key finances.

Pitch Rated

48%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £246,046
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph